atai Therapeutics, Inc. clinical trials
Acquired by Eli Lilly and Company, Sep 11, 2026 · source ↗
The registry lists 3 studies whose lead sponsor is atai Therapeutics, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 30, 2026.
- 3studies on the registry
- 0open to participants now
Before and after it joined Eli Lilly and Company
- First submitted before atai Therapeutics, Inc. became part of Eli Lilly and Company
- 3
- First submitted after atai Therapeutics, Inc. became part of Eli Lilly and Company
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs atai Therapeutics, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 1
All 3 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed3100%
Over the years
- 121
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- atai Therapeutics, Inc.3 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Eli Lilly and Company studies →
- A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)CompletedNCT06524830Phase 2
Sponsor listed in the registry: atai Therapeutics, Inc. · First submitted before atai Therapeutics, Inc. became part of Eli Lilly and Company
- Exploratory Safety and Efficacy of EMP-01 in Social Anxiety DisorderCompletedNCT06693609Phase 2
Sponsor listed in the registry: atai Therapeutics, Inc. · First submitted before atai Therapeutics, Inc. became part of Eli Lilly and Company
- A Study of Oral Ibogaine in Opioid WithdrawalCompletedNCT05029401Phase 1/2
Sponsor listed in the registry: atai Therapeutics, Inc. · First submitted before atai Therapeutics, Inc. became part of Eli Lilly and Company